Target RWE partners with the American Association for the Study of Liver Diseases to support its Cirrhosis Quality Collaborative

Target RWE and the American Association for the Study of Liver Diseases announce partnership to leverage RWD for the Cirrhosis Quality Collaborative to advance progress in research and improve quality of care and outcomes for patients with liver disease.

Target RWE, a leader in RWE, has recently announced an immediately effective partnership with the American Association for the Study of Liver Diseases (AASLD). Strategically combining their complementary expertise will enable leveraging of RWD from across the USA for AASLD’s Cirrhosis Quality Collaborative (CQC), with the goals of advancing progress in research and improving quality of care and outcomes for patients with liver disease.

AASLD is the leading organization of clinicians and researchers committed to preventing and curing liver disease. CQC, a multi-site learning health network, is an initiative of AASLD that combines quality improvement and research to optimize the management and outcomes of patients with cirrhosis. Target RWE will contribute its knowledge of long-term, observational studies and data collection and analytics capabilities to the established CQC network, facilitating its expansion and longer-term goal planned under the TARGET-Liver Disease protocol.

“This partnership will allow us to expand the number of sites, while continuing the automated interface model that permits rapidly enrolling thousands of patients with cirrhosis,” said CQC Co-Chair Michael Volk, Fellow of AASLD (FAASLD). “This will support a much greater contribution to research and quality improvement than can be done with single center studies.”

CQC Co-Chair, Fasiha Kanwal, FAASLD, continued, “This partnership with Target RWE provides significant value to the CQC and to the liver community. It provides a platform for ongoing learning, hypothesis generation, and data analysis to support clinical and quality improvement protocols as well as patient-centered research. It can also play a key role in the development of the next generation of hepatologists, engaging them in research using a large and diverse dataset representing patients with all etiologies of liver disease,”.

The collaborative will aggregate data generated directly as part of the clinical care for thousands of patients with cirrhosis from multiple centers across the US. Target RWE will provide the operational teams to oversee the networked site activities and all data services supporting cohort building, data curation, provision of datasets and customized advanced analytics.

“This innovative collaboration allows for streamlined workflows and comprehensive, high-quality data collection paired with specialized Target RWE analytic methodology to address the challenges of using data from real-world sources. We are thrilled to be able to partner with AASLD to advance understanding in the field of cirrhosis as a part of the CQC,” said Michael Fried, Co-founder and CMO of Target RWE, FAASLD and former President of AASLD.

AASLD will work with the networked sites and Target RWE to ensure the research aims and quality initiatives are carried out and to promote evidence-based innovation for patients with liver disease.

“This exciting new agreement advances AASLD’s longstanding mission in research and care of patients with cirrhosis by leveraging Target RWE capabilities and experience with real world data cohorts, data curation, and evidence generation,” explained Laurie DeLeve, President of AASLD. “The outcomes from this research will help us identify areas of improvement for patient care which can then be used to develop educational content and health system resources to address care gaps in specific areas.”